Digital health technology in clinical trials.
Mittermaier. Mirja M; Venkatesh. Kaushik P KP; Kvedar. Joseph C JC
Key Findings
- Digital health tech lets researchers gather real‑world data outside clinics
- Challenges include standardizing digital measurements and the risk of leaving out people without good internet or devices
- Neurology trials have increasingly used wearables over the past decade
Practical Outcomes
- There’s no immediate, actionable advice for biohackers looking to use kpv. The main takeaway is that while digital tools are growing in research, they don’t change how you’d dose or experiment with this peptide.
Summary
The paper talks about how wearable devices and other digital tools are being used in clinical trials to collect data from people at home, but it doesn’t give any direct tips for using the peptide kpv or for personal health hacks.
Abstract
Digital health technologies (DHTs) have brought several significant improvements to clinical trials, enabling real-world data collection outside of the traditional clinical context and more patient-centered approaches. DHTs, such as wearables, allow the collection of unique personal data at home over a long period. But DHTs also bring challenges, such as digital endpoint harmonization and disadvantaging populations already experiencing the digital divide. A recent study explored the growth trends and implications of established and novel DHTs in neurology trials over the past decade. Here, we discuss the benefits and future challenges of DHT usage in clinical trials.
Study Information
pubmed
2023
2023-05-18T00:00:00.000Z
10.1038/s41746-023-00841-8
32
24